Craig Burton on Inflation Reduction Act

The prescription drug negotiation provisions in the Inflation Reduction Act grant the Medicare agency significant regulatory authority to lower prices for high-expenditure drugs, but there’s a high degree of uncertainty as to how the law will impact generic and biosimilar competition, according to Craig Burton, senior vice president of the Association for Accessible Medicines. Burton joins Bloomberg Intelligence analysts Duane Wright and Letitia Walker on this episode of the Votes and Verdicts podcast to discuss the potential impact of drug-pricing negotiation provisions and the Part D redesign on research and marketing strategies for the generic and biosimilar industry. Burton also shares his views on drug shortages and key pillars for industry. See omnystudio.com/listener for privacy information.